

Investors Newsletter

Number 6

February 1 2015



To our Partners, Friends and Shareholders:

Last month our S1 prospectus was approved by the SEC. As promised $\frac{1}{4}$ of the investors shares are free for trading. As of now E-QURE has appx. 2.5 million Shares trading out of the 21.6 million outstanding. The company is trading with its new symbol EQUR.

As we reported, we have raised additional \$230,000 of equity from prominent investors that adds additional credibility to our company. This, in order to have backup cousin financing into 2016 toward trial completion.

On January 1, 2015, we have submitted to the FDA our trial documentations and applications, after implementing FDA comments from previous rounds. If no additional comments will be received from FDA, we will be able to start our US clinical trial soon.

We succeeded to return to our possession a substantial number of working devices that was laying at an Austrian warehouse. We are currently testing them and putting them back to active use.



Devices shipment arrives from Austria

As a result of further discussion with the FDA, we have added into our trial protocol the use of Sham device that will treat the control group. This makes our trial more complicated to manage, but will enhance substantially the results' significance validity. The scientific advisory board conducted a brainstorming session in January to prepare for trial initiation.



Dr. Weiner and Prof. Ohri in a creative brainstorming session.

We decided to refresh the company production capabilities in order to be ready for start of commercialization. We have identified two possible subcontractors that can manufacture our device in the required quality standards. We will now negotiate the terms and decide which one to use as our production facility



Screening visit in a production facility

Investors Newsletter

Number 6

February 1 2015



A research report on our company was published on January 30 2015 by Zacks Investment Research Company in the USA. Zacks is a premier research company issuing recommendations for companies it is following. Please see www.zacks.com. A copy of the research report will be sent to you separately.



Zacks Small-Cap Research

scr.zacks.com

10 S. Riverside Plaza, Chicago, IL 60606

January 30, 2015
Anita D'Amico, PhD
312-269-9414
ad@zacks.com

Robert Baskin, CPA
312-269-9414
rbaskin@zacks.com

E-Qure Corp

(EQUR-OTC)

EQUR: WOUND HEALING WITH ELECTRICAL STIMULATION

Current Recommendation
Prior Recommendation
Date of Last Change

Outperform
N/A
1/30/2015

Current Price (01/30/2015)
Target Price

\$1.14
\$3.50

OUTLOOK

EQUR has developed an effective, low cost, easy-to-use device for chronic wound management, which addresses a market worth about \$6 billion annually. Results from clinical trials have been very encouraging. Recruitment of patients for a study which is expected to support an FDA filing is underway. We think FDA approval could happen before end of 2016 and product launch in the U.S. could happen towards mid-2017. We think EQUR has a compelling story and believe valuation might increase as certain risks abate. Our target price is \$3.50/ share. We are initiating coverage with an Outperform rating.

.A snapshot of the first page from the research report published Jan 30 2015

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. We are using forward-looking statements, when we discuss items in this document. These forward-looking statements and their implications are based on the current expectations of the management of E-QURE only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of E-QURE to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, E-QURE undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting E-QURE, reference is made to E-QURE's reports filed from time to time with the Securities and Exchange Commission.